Intra-Cellular Therapies, Inc. financial data

Location
Bedminster, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 21 Feb 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 678% % -2.6%
Quick Ratio 13% % -59%
Debt-to-equity 18% % -4.6%
Return On Equity -7% % 68%
Return On Assets -6% % 68%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106,521,576 shares 0.9%
Common Stock, Shares, Outstanding 106,240,009 shares 10%
Entity Public Float $7,100,000,000 USD 18%
Common Stock, Value, Issued $11,000 USD 10%
Weighted Average Number of Shares Outstanding, Basic 103,131,017 shares 7.6%
Weighted Average Number of Shares Outstanding, Diluted 103,131,017 shares 7.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $680,852,000 USD 47%
Research and Development Expense $236,121,000 USD 31%
General and Administrative Expense $471,480,000 USD 18%
Operating Income (Loss) $116,721,000 USD 27%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $74,203,000 USD 47%
Income Tax Expense (Benefit) $473,000 USD -26%
Net Income (Loss) Attributable to Parent $74,676,000 USD 47%
Earnings Per Share, Basic -1 USD/shares 50%
Earnings Per Share, Diluted -1 USD/shares 50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $306,948,000 USD 108%
Accounts Receivable, after Allowance for Credit Loss, Current $166,500,000 USD 46%
Inventory, Net $26,283,000 USD 126%
Assets, Current $1,307,364,000 USD 96%
Property, Plant and Equipment, Net $1,468,000 USD -11%
Operating Lease, Right-of-Use Asset $13,428,000 USD 3.9%
Other Assets, Noncurrent $5,762,000 USD -21%
Assets $1,366,912,000 USD 88%
Accounts Payable, Current $26,074,000 USD 128%
Liabilities, Current $205,704,000 USD 67%
Operating Lease, Liability, Noncurrent $12,748,000 USD -4.3%
Liabilities $218,452,000 USD 60%
Accumulated Other Comprehensive Income (Loss), Net of Tax $191,000 USD 84%
Retained Earnings (Accumulated Deficit) $1,691,836,000 USD -4.6%
Stockholders' Equity Attributable to Parent $1,148,460,000 USD 94%
Liabilities and Equity $1,366,912,000 USD 88%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,116,000 USD 43%
Net Cash Provided by (Used in) Financing Activities $9,989,000 USD 174%
Net Cash Provided by (Used in) Investing Activities $16,179,000 USD
Common Stock, Shares Authorized 175,000,000 shares 0%
Common Stock, Shares, Issued 106,240,009 shares 10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,948,000 USD 89%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $308,698,000 USD 106%
Deferred Tax Assets, Valuation Allowance $297,449,000 USD 9.9%
Operating Lease, Liability $16,981,000 USD 0.25%
Depreciation $132,000 USD -1.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $74,589,000 USD 45%
Lessee, Operating Lease, Liability, to be Paid $20,685,000 USD -4.3%
Operating Lease, Liability, Current $4,233,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,513,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,435,000 USD 17%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,704,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $4,573,000 USD 15%
Deferred Tax Assets, Operating Loss Carryforwards $130,066,000 USD -6.2%
Unrecognized Tax Benefits $2,400,000 USD -4%
Lessee, Operating Lease, Liability, to be Paid, Year Four $4,707,000 USD 17%